PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR (PROGRESS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04889872 |
Recruitment Status :
Recruiting
First Posted : May 17, 2021
Last Update Posted : April 29, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis.
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Aortic Stenosis, Calcific Aortic Valve Stenosis | Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 2250 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The PROGRESS Trial: A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement |
Actual Study Start Date : | October 12, 2021 |
Estimated Primary Completion Date : | June 2029 |
Estimated Study Completion Date : | June 2037 |
Arm | Intervention/treatment |
---|---|
Experimental: TAVR
Transcatheter Aortic Valve Replacement (TAVR)
|
Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve |
No Intervention: CS
Clinical Surveillance (CS)
|
- Primary Effectiveness Endpoint [ Time Frame: 2 years ]Non-hierarchical composite of death, and heart failure hospitalization or event
- Primary Safety Endpoint [ Time Frame: 30 days ]Non-hierarchical composite of death, stroke, life threatening or fatal bleeding, acute kidney injury stage 4, hospitalization due to device- or procedure-related complication, and valve dysfunction requiring reintervention
- Death, stroke, or unplanned cardiovascular hospitalization [ Time Frame: 2 years ]The number of patients that had this event
- Death, unplanned cardiovascular hospitalization, or decrease of > 10 points in Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: 2 years ]The number of patients that met all these criteria
- Unplanned cardiovascular hospitalization [ Time Frame: 2 years ]The number of patients that had this event
- Left ventricle (LV) mass index [ Time Frame: 2 years ]Echocardiographic measurement of the size of the left ventricle
- Stroke volume index [ Time Frame: 2 years ]Echocardiographic measurement of the volume of blood pumped out of the left ventricle during contraction.
- Diastolic dysfunction ≥ Grade 2 [ Time Frame: 2 years ]Echocardiographic measurement of the stiffness of the left ventricle.
- N-Terminal Pro B-type Natriuretic Peptide (NT-ProBNP) [ Time Frame: 2 years ]NT-ProBNP is a hormone that measures heart failure. Levels goes up when heart failure develops or gets worse, and levels goes down when heart failure is stable.
- KCCQ overall score [ Time Frame: 2 years ]Change from baseline in KCCQ. The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
- Reduction in LVEF ≥ 5% from baseline AND LVEF < 60% [ Time Frame: 2 years ]The number of patients that meet these criteria
- New onset atrial fibrillation [ Time Frame: 2 years ]The number of patients that develop this condition
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- 65 years of age or older at time of randomization
- Moderate aortic stenosis
- Subject has symptoms or evidence of cardiac damage/dysfunction
- The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.
Key Exclusion Criteria:
- Native aortic annulus size unsuitable for the THV
- Anatomical characteristics that would preclude safe transfemoral placement of the introducer sheath or safe passage of the delivery system
- Aortic valve is unicuspid or non-calcified
- Bicuspid aortic valve with an aneurysmal ascending aorta > 4.5 cm or severe raphe/leaflet calcification
- Pre-existing mechanical or bioprosthetic aortic valve
- Severe aortic regurgitation
- Prior balloon aortic valvuloplasty to treat severe AS
- LVEF < 20%
- Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant paravalvular leak post-TAVR
- Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation
- Coronary or aortic valve anatomy that increases the risk of coronary artery obstruction post-TAVR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04889872
Contact: Edwards THV Clinical Affairs | 949-250-2500 | THV_CT.gov@Edwards.com |
Principal Investigator: | Philippe Généreux, MD | Morristown Medical Center, Morristown, NJ, USA | |
Principal Investigator: | Jeroen J Bax, MD, PhD | Leiden University Medical Center, Leiden, The Netherlands | |
Principal Investigator: | Raj Makkar, MD | Cedars-Sinai Medical Center, Los Angeles, CA, USA |
Responsible Party: | Edwards Lifesciences |
ClinicalTrials.gov Identifier: | NCT04889872 |
Other Study ID Numbers: |
2021-01 |
First Posted: | May 17, 2021 Key Record Dates |
Last Update Posted: | April 29, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Transcatheter aortic valve replacement (TAVR) SAPIEN 3 SAPIEN 3 Ultra SAPIEN 3 Ultra RESILIA |
Moderate aortic stenosis Aortic stenosis Transcatheter heart valve |
Aortic Valve Stenosis Constriction, Pathologic Pathological Conditions, Anatomical Aortic Valve Disease |
Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |